Investigating Therapies for Freezing of Gait
24 april 2017 bijgewerkt door: Rebecca Chow, Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Investigating Therapies for Freezing of Gait Targeting the Cognitive, Limbic, and Sensorimotor Domains
Freezing of gait (FOG) is arguably one of the most debilitating motor symptoms experienced by individuals with Parkinson's disease (PD).
FOG may be caused by an overload of cognitive, limbic, and sensorimotor system activity in the basal ganglia.
Therefore, the purpose of this study is to evaluate cognitive, limbic, and sensorimotor therapies in individuals with FOG.
Participants in this study will undergo all three types of treatments in a randomized counterbalanced order.
Each treatment will occur in 1 hour sessions, twice weekly for a period of 4 weeks.
Studie Overzicht
Toestand
Onbekend
Interventie / Behandeling
Gedetailleerde beschrijving
Freezing of gait (FOG) is arguably one of the most debilitating motor symptoms experienced by individuals with Parkinson's disease (PD), and negatively impacts quality of life (Walton et al., 2015). Furthermore, advanced FOG does not respond well to treatments commonly used in Parkinson's disease (Nutt et al., 2011), therefore warranting the use of adjunct treatment options. The development of potential treatment strategies for FOG should focus on the underlying mechanism. The cross-talk model of FOG proposes that FOG may be caused by an overload of cognitive, limbic, and sensorimotor system activity in the basal ganglia, resulting in a depletion of dopaminergic resources, leading to FOG (Lewis & Barker, 2009). Hence, based on the cross-talk model, treatments targeting the cognitive, sensorimotor and limbic systems independently may lead to a reduction in FOG episodes. Previous studies have demonstrated the efficacy of therapies targeting these domains in PD and healthy individuals, however, these have yet to be explored in FOG. Therefore, the purpose of this study is to evaluate cognitive, sensorimotor, and limbic therapies in individuals with FOG.
This study will employ a within-subjects design, in which participants will undergo all three treatments in a randomized counterbalanced order. Sessions for each type of treatment will occur for 1 hour, twice weekly for a period of 4 weeks. Participants will also undergo pre- and post-test assessments prior to and following each 4-week treatment period. The cognitive training will utilize the "Smartbrain Pro" computer software, which has previously demonstrated efficacy in individuals with Parkinson's disease (Paris et al., 2011). The sensorimotor training group will participate in proprioceptive training of the upper and lower limbs. This training will entail a target matching task, in which participants will produce active and self-defined movements while blindfolded (i.e. without visual feedback). The limbic training group will undergo cognitive behavioural therapy (CBT) focusing solely on anxiety symptoms.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
17
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Ontario
-
Waterloo, Ontario, Canada, N2L 3C5
- Sun Life Financial Movement Disorders Research and Rehabilitation Centre
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Either gender
- Diagnosed with idiopathic PD by a Neurologist
- Self-reported FOG with the use of UPDRS-II (Question 14)
- Confirmation of present FOG by a movement disorder specialist
- Able to walk 10 meters, unassisted
- Able to understand English instructions
Exclusion Criteria:
- A neurological disease other than PD
- Peripheral neuropathy
- Clinically diagnosed with dementia
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cognitive Training
Participants will independently complete cognitive exercises on the "Smartbrain Pro" computer software.
These exercises aim to train different aspects of executive function.
The difficulty level of each exercise will increase relative to each participant's progress.
Sessions will last for one hour, occurring twice weekly for a period of 4 weeks.
|
Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g.
visuospatial processing, executive function, memory, language, and attention).
Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD.
Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
|
|
Experimenteel: Cognitive Behavioural Therapy
Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety.
Participants will complete a total of eight one-hour sessions over 4 weeks.
|
CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD.
This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG.
During periods of elevated anxiety (e.g.
walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
|
|
Experimenteel: Proprioceptive Training
Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs.
For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets.
They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on.
The blindfold will then be removed allowing participants to view their performance relative to the target.
This task will be repeated for the remaining targets on both sides and for both upper and lower limbs.
Participants will complete a total of eight one-hour sessions over 4 weeks.
|
Currently, studies investigating proprioceptive training as a treatment in PD are limited.
However, this type of training has potential by improving proprioceptive processing.
It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Gait Assessment
Tijdsspanne: Change from Baseline at 4 weeks of first treatment phase
|
Participants will walk approximately 9.75 metres for 12 trials.
Recording of kinematic data will be done with eight Optotrak® cameras (Northern Digital, NDI, Waterloo, Ontario).
Spatiotemporal gait parameters will be analyzed from this assessment.
|
Change from Baseline at 4 weeks of first treatment phase
|
|
Gait Assessment
Tijdsspanne: Change from Baseline at 4 weeks of second treatment phase
|
Participants will walk approximately 9.75 metres for 12 trials.
Recording of kinematic data will be done with eight Optotrak® cameras (Northern Digital, NDI, Waterloo, Ontario).
Spatiotemporal gait parameters will be analyzed from this assessment.
|
Change from Baseline at 4 weeks of second treatment phase
|
|
Gait Assessment
Tijdsspanne: Change from Baseline at 4 weeks of third treatment phase
|
Participants will walk approximately 9.75 metres for 12 trials.
Recording of kinematic data will be done with eight Optotrak® cameras (Northern Digital, NDI, Waterloo, Ontario).
Spatiotemporal gait parameters will be analyzed from this assessment.
|
Change from Baseline at 4 weeks of third treatment phase
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Stroop Test
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of first treatment phase
|
This test assesses inhibitory control and will be administered in a paper-based format.
|
Pre-intervention and Post-intervention at week 4 of first treatment phase
|
|
Trail-making test
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of first treatment phase
|
This will also be administered in a paper-based format.
This test will assess visuospatial function and set-shifting ability.
|
Pre-intervention and Post-intervention at week 4 of first treatment phase
|
|
Stroop Test
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of second treatment phase
|
This test assesses inhibitory control and will be administered in a paper-based format.
|
Pre-intervention and Post-intervention at week 4 of second treatment phase
|
|
Trail-making test
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of second treatment phase
|
This will also be administered in a paper-based format.
This test will assess visuospatial function and set-shifting ability.
|
Pre-intervention and Post-intervention at week 4 of second treatment phase
|
|
Stroop Test
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of third treatment phase
|
This test assesses inhibitory control and will be administered in a paper-based format.
|
Pre-intervention and Post-intervention at week 4 of third treatment phase
|
|
Trail-making test
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of third treatment phase
|
This will also be administered in a paper-based format.
This test will assess visuospatial function and set-shifting ability.
|
Pre-intervention and Post-intervention at week 4 of third treatment phase
|
|
Passive Joint Angle Matching
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of first treatment phase
|
This task will be assessed in order to evaluate proprioceptive functioning.
|
Pre-intervention and Post-intervention at week 4 of first treatment phase
|
|
Passive Joint Angle Matching
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of second treatment phase
|
This task will be assessed in order to evaluate proprioceptive functioning.
|
Pre-intervention and Post-intervention at week 4 of second treatment phase
|
|
Passive Joint Angle Matching
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of third treatment phase
|
This task will be assessed in order to evaluate proprioceptive functioning.
|
Pre-intervention and Post-intervention at week 4 of third treatment phase
|
|
Parkinson Anxiety Scale
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of first treatment phase
|
The Parkinson Anxiety Scale (PAS), which is a self-report questionnaire used to assess anxiety levels, will be administered to participants.
This tool has demonstrated good concurrent validity in individuals with PD against other existing anxiety scales (Leentjens et al., 2014).
|
Pre-intervention and Post-intervention at week 4 of first treatment phase
|
|
Parkinson Anxiety Scale
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of second treatment phase
|
The Parkinson Anxiety Scale (PAS), which is a self-report questionnaire used to assess anxiety levels, will be administered to participants.
This tool has demonstrated good concurrent validity in individuals with PD against other existing anxiety scales (Leentjens et al., 2014).
|
Pre-intervention and Post-intervention at week 4 of second treatment phase
|
|
Parkinson Anxiety Scale
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of third treatment phase
|
The Parkinson Anxiety Scale (PAS), which is a self-report questionnaire used to assess anxiety levels, will be administered to participants.
This tool has demonstrated good concurrent validity in individuals with PD against other existing anxiety scales (Leentjens et al., 2014).
|
Pre-intervention and Post-intervention at week 4 of third treatment phase
|
|
Unified Parkinson's disease Rating Scale Motor Subsection (UPDRS-III)
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of first treatment phase
|
A clinician administered assessment which evaluates individuals' motor symptom severity
|
Pre-intervention and Post-intervention at week 4 of first treatment phase
|
|
Unified Parkinson's disease Rating Scale Motor Subsection (UPDRS-III)
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of second treatment phase
|
A clinician administered assessment which evaluates individuals' motor symptom severity
|
Pre-intervention and Post-intervention at week 4 of second treatment phase
|
|
Unified Parkinson's disease Rating Scale Motor Subsection (UPDRS-III)
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of third treatment phase
|
A clinician administered assessment which evaluates individuals' motor symptom severity
|
Pre-intervention and Post-intervention at week 4 of third treatment phase
|
|
New Freezing of Gait Questionnaire (NFOGQ)
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of first treatment phase
|
Participants will be asked to complete the New Freezing of Gait Questionnaire (NFOGQ) questionnaire developed by Nieuwboer and colleagues (2009).
This provides a self-reported measure of frequency and duration of FOG episodes.
This tool has been validated and proven to be highly reliable in individuals with PD, as well as assessing treatment interventions for FOG.
|
Pre-intervention and Post-intervention at week 4 of first treatment phase
|
|
New Freezing of Gait Questionnaire (NFOGQ)
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of second treatment phase
|
Participants will be asked to complete the New Freezing of Gait Questionnaire (NFOGQ) questionnaire developed by Nieuwboer and colleagues (2009).
This provides a self-reported measure of frequency and duration of FOG episodes.
This tool has been validated and proven to be highly reliable in individuals with PD, as well as assessing treatment interventions for FOG.
|
Pre-intervention and Post-intervention at week 4 of second treatment phase
|
|
New Freezing of Gait Questionnaire (NFOGQ)
Tijdsspanne: Pre-intervention and Post-intervention at week 4 of third treatment phase
|
Participants will be asked to complete the New Freezing of Gait Questionnaire (NFOGQ) questionnaire developed by Nieuwboer and colleagues (2009).
This provides a self-reported measure of frequency and duration of FOG episodes.
This tool has been validated and proven to be highly reliable in individuals with PD, as well as assessing treatment interventions for FOG.
|
Pre-intervention and Post-intervention at week 4 of third treatment phase
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Rebecca Chow, BSc, Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
24 februari 2017
Primaire voltooiing (Verwacht)
1 augustus 2017
Studie voltooiing (Verwacht)
1 augustus 2017
Studieregistratiedata
Eerst ingediend
9 februari 2017
Eerst ingediend dat voldeed aan de QC-criteria
21 februari 2017
Eerst geplaatst (Werkelijk)
27 februari 2017
Updates van studierecords
Laatste update geplaatst (Werkelijk)
25 april 2017
Laatste update ingediend die voldeed aan QC-criteria
24 april 2017
Laatst geverifieerd
1 april 2017
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- SunLife
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Nee
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .